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Background: Pediatric multiple sclerosis (MS) is a rare disorder with significant consequences. Quantitative MRI
measurements may provide significant insights, however multicenter collaborative studies are needed given the
small numbers of subjects. The goal of this study is to demonstrate feasibility and evaluate lesion volume (LV)
characteristics in a multicenter cohort of children with MS.
Methods: A common MRI-scanning guideline was implemented at six member sites of the U.S. Network of
Pediatric MS Centers of Excellence. We included in this study the first ten scans performed at each site on patients
meeting the following inclusion criteria: pediatric RRMS within 3 years of disease onset, examination within 1 month
of MRI and no steroids 1 month prior to MRI. We quantified T2 number, T2-LV and individual lesion size in a total of
53 MRIs passing quality control procedures and assessed gadolinium-enhancing lesion number and LV in 55 scans.
We studied MRI measures according to demographic features including age, race, ethnicity and disability scores,
controlling for disease duration and treatment duration using negative binomial regression and linear regression.
Results: The mean number of T2 lesions was 24.30 ± 19.68 (range:1–113) and mean gadolinium-enhancing lesion
count was 1.85 ± 5.84, (range:0–32). Individual lesion size ranged from 14.31 to 55750.60 mm3. Non-white subjects
had higher T2–LV (unadjusted pT2-LV = 0.028; adjusted pT2-LV = 0.044), and maximal individual T2-LV (unadjusted
pMax = 0.007; adjusted pMax = 0.011) than white patients. We also found a trend toward larger mean lesion size in
males than females (p = 0.07).
Conclusion: Assessment of MRI lesion LV characteristics is feasible in a multicenter cohort of children with MS.Background
Multiple sclerosis (MS) is an increasingly recognized dis-
order in children and adolescents. The onset of MS prior
to the age of 18 occurs in 3-5% of the total MS popula-
tion [1-3]. Children and adolescents with MS have
higher relapse rates than adults with the disease [4],
suggesting inflammation as a prominent feature. Chil-
dren also demonstrate considerable cognitive disability
early in the disease course [5-7] but relatively less* Correspondence: tchitnis@rics.bwh.harvard.edu
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reproduction in any medium, provided the orlocomotor disability than adults with a similar disease
duration [8].
MRI features of pediatric MS may provide further insight
into these clinical observations. Studies have suggested that
younger children with MS present with atypical MRI fea-
tures [9], and brain T2 lesion load appears relatively higher
at disease presentation in pediatric-onset patients than
adult-onset MS [10]. Others have suggested gender differ-
ences in lesion location in children with clinically isolated
syndromes [11].
The goal of this cross-sectional multicenter pilot study
was to evaluate MRI burden of disease using quantitative
measures in a cohort of children and adolescents withLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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MRI measures according to demographic features in-
cluding age, race and ethnicity, and disability scores.
Methods
Patients
MS patients were seen at one of the six U.S. Network
of Pediatric MS Centers of Excellence located in San
Francisco, CA (UCSF), Rochester, MN (Mayo), Birmingham,
AL (UAB), Buffalo, NY (SUNY Buffalo), Stony Brook,
NY (SUNY Stony Brook), and Boston, MA (MGH). In
this pilot study, we obtained MRI scans from the first 10
subjects at each site (60 subjects total) who met the follow-
ing inclusion criteria: 1) Diagnosis of RRMS and onset
under 18 years using the International Pediatric MS Study
Group diagnostic criteria [12]; 2) MRI performed using
our standardized Network Pediatric MS MRI guidelines; 3)
MRI performed less than 3 years from first symptom onset;
4) Clinical examination performed within 1 month of MRI
(no acute relapse in between MRI and examination); and
5) No steroids administered 30 days prior to MRI scans.
We collected MRI scans from ten patients at each site.
Demographic data, including age at disease onset, EDSS,
self-identified race and ethnicity and treatment history,
were collected using a standardized database and are pre-
sented in Table 1. This study was conducted in compliance
to the Helsinki Declaration. We obtained IRB approval for
this study at all sites from the following ethics boards: Part-
ners Human Research Committee (MGH), Health SciencesTable 1 Baseline demographic and MRI features of
subject cohort
Characteristic
Number of subjects (N) 57
Gender [N (%) female] 38 (66.7%)
Race [N (%) self-reported white] 40 (70.2%)
Ethnicity [N (%) self-reported Hispanic/Latino] 14 (24.5%)
Age [years, mean+/−SD, (range)] 14.78 +/− 3.12 (5, 18)
Disease duration [days, mean+/−SD] 564.04 +/− 440.69
Disease modifying therapy (DMT) [N (%)] 38 (66.7%)
Time on DMT [days, mean +/− SD, (range)]* 206.57 +/− 207.76
(0, 702)
EDSS [mean +/− SD, (range)]** 1.1 +/− 1.0 (0, 4.0)
EDSS [median, (range)]** 1.0 (0.4.0)
T2 lesion count [mean +/− SD, (range)]^ 24.30+/−19.68 (1,113)




GD + lesion count [mean +/− SD, (range)]† 1.85 +/− 5.84, (0, 32)




Legend: * = 3 subjects missing, ** = 1 subjects missing, ^=4 subjects missing,
† = 2 subjects missing, †† = among 19 subject with GD + lesions, EDSS =
Expanded Disability Status Scale.Institutional Review Board (SUNY-Buffalo), Stonybrook
University IRB (SUNY-Stonybrook), University of Alabama
IRB (UAB), UCSF Human Research Protection Program
(UCSF), Mayo Clinic IRB (Mayo Clinic). Signed informed
consent from a parent or guardian for children under
the age of 18 was required by the IRB boards at all sites
except MGH.
MRI acquisition
Subjects underwent MRI at 1.5 T. Four sites used a 1.5 T
General Electric (Milwaukee, WI, USA) Signa Excite HDx
scanner. One site used Philips (Best, the Netherlands)
Intera Gyroscan scanner, and another site used Siemens
(Erlangen, Germany) Avanto scanner. The Pediatric MS
Network protocol consisted of a standardized protocol. The
protocol included a two-dimensional (2D) double-echo
proton density (PD) and T2-weighted (T2W) spin-echo
(SE) sequence [repetition time (TR) = 3200–3500 ms, first
and second echo time (TE1/TE2) = 12-15/90-105 ms, FA =
90°, field of view (FOV) = 256 mm, phase FOV (pFOV) =
75%, acquisition matrix = 256×192 for an in-plane reso-
lution of 1×1 mm, slice thickness = 3 mm, NEX= 1], a 2D
Fluid Attenuated Inversion Recovery (FLAIR) sequence
[TR = 8000–11000 ms, TE = 93–140 ms, inversion time
(TI) = 2200–2250 ms, FA = 90°, FOV= 256 mm, pFOV=
75%, acquisition matrix = 256×192 for an in-plane reso-
lution of 1×1 mm, slice thickness = 3 mm, NEX= 1], a 2D
T1-weighted (T1-W) SE sequence post-contrast contrast
agent injection (0.1 mmol/kg with 5 minutes of delay)
[TR = 500–717 ms, TE = 20 ms, FA = 90°, FOV= 256 mm,
pFOV= 75%, acquisition matrix = 256×192 for an in plane
resolution of 1×1 mm, slice thickness = 3 mm, NEX= 1],
and a sagittal three-dimensional (3D) T1W spoiled gradient
recalled echo (SPGR) sequence.
MRI analysis
Image distribution and quality control
We used an image-transfer and process- dispatching sys-
tem based on service-oriented architecture (SOA). Data
flow and process-coordinating webservices (WS) were
deployed at the Center for Neurological Imaging, BWH,
Boston, MA. A data-flow system with central quality
control for series identification, protocol compliance,
visual inspection was implemented at BWH. Lesion seg-
mentation and volumetric analysis were performed at
the Buffalo Neuroimaging Analysis Center, Buffalo, NY.
Operators were blinded to patient clinical status.
Lesion numbers and volume
Calculation of the number, size and total volume of T2
lesions was performed on FLAIR images that were co-
registered to PD/T2-WIs. The gadolinium-enhancing
(GD+) lesion analysis was performed on SE-T1-WIs,
whereas the 3D T1-SPGR images were used as a reference
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sponding pre-contrast scans. The analysis was based on
a semi-automated tracing method using computer-
displayed images, as previously described. [10,13] For
each individual lesion, the total number of voxels con-
tained within the lesion was calculated using a fully
automated connected-components algorithm [14]. The
size for each lesion was then obtained by multiplying
the number of voxels circumscribed within the lesion by
the volume of the voxel. We recorded total volume of
lesions as well as individual lesion size for each subject.
Statistical methods
The main outcome measures for this study were the num-
ber of T2 lesions, number of GD+ lesions, total T2 lesion
volume (LV) and maximum lesion size for each subject. The
potential predictors of these outcome variables were demo-
graphic (age, gender, race, and ethnicity) or clinical (EDSS).
For all analyses, the lesion volumes were log-transformed to
account for the right skew in the data. In each analysis, uni-
variate and multivariate models that adjusted for disease
duration and treatment duration at the time of the MRI
scan were fit. The associations between the total lesion
number and the potential predictors were assessed using
negative binomial regression, and the association between
the log-transformed total lesion volumes and the potential
predictors were assessed using linear regression. In addition
to these analyses, we also measured the size of each individ-
ual lesion in each subject (1288 T2 lesions in 53 subjects
with MRIs that passed T2 sequence QC). To assess the ef-
fect of the predictors on the average lesion size, a repeated-
measures model with a compound symmetry covariance
















Figure 1 Box-plot of volumes of T2 lesions within each subject (mm3correlation of lesion sizes within a subject. Data analysis was
performed utilizing the statistical software package, SAS
Version 9.1.3 Service Pack 4, and a p-value of <0.05 was
considered statistically significant in all analyses.
Results
Patients
MRI scans from 57 subjects passed general quality control
criteria and underwent quantitative MRI analysis. Baseline
demographic and MRI characteristics of these subjects are
summarized in Table 1. The demographic characteristics of
the pediatric MS subjects were similar to other studies in
the U.S. [3,4] in that the percentage of subjects self-
identifying as non-white or Hispanic was higher than in
typical adult cohorts. In addition, the mean disease duration
since first symptom was less than two years so that the ob-
served MRIs were performed soon after disease onset. The
mean MRI measures are also listed in Table 1. Of the 57
available scans for MRI analysis, we calculated total T2-LV
and T2 lesion numbers from 53 scans, since four scans did
not pass quality control for T2 measures. Of these 53 sub-
jects, all had at least one T2 lesion. Similarly, because of
quality control, total Gd-LV and number was calculated
from 55 scans, 19 (34.5%) of which had at least one Gd + le-
sion. The mean number of T2 lesions was 24.30 ± 19.68
(range:1–113), and mean gadolinium-enhancing lesion
count was 1.85 ± 5.84, (range:0–32). Mean T2-LV was
10489.28 ± 12477.55, and mean gadolinium-enhancing
LV was 710.35 ± 1739.87. Figure 1 depicts box-plots of
individual T2 lesion size within each subject. Individual
lesion size ranged from 14.31 to 55750.60 mm3. The
mean (SD) of the difference between the largest and
smallest lesion size within a subject was 5189 (10046)): lesion size is plotted on a log-transformed scale.
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within a patient. Table 2 demonstrates associations be-
tween the demographic/clinical predictors and T2 le-
sion number, total T2-LV and the maximum lesion size.
Age
The mean age of subjects was 14.78 +/− 3.12 years
reflecting the predilection for MS during the adolescent
years. When analyzing MRI measurements, we observed
no statistically significant associations between age and
any of the T2 lesion measurements (Table 2) or number
of GD + lesions (adjusted p = 0.84).
Gender
Our model showed no statistically significant associa-
tions with any of the T2-LV or T2 lesion number mea-
surements and gender. However, males in our model
demonstrated a trend towards larger mean lesion size
(adjusted p = 0.07) (Table 2). There was no statistically
significant association between GD + lesion number and
gender (adjusted p = 0.99).
Race
We divided patients into groups of white and non-white
patients, of which the latter contained both African-
American patients and others (African-American = 8,
Mixed origin and other = 8, American Indian = 1). WeTable 2 Estimate and 95% confidence interval for the effect o
Factor Analysis Rate ratio for T2
lesion number*
Age Unadjusted 1.00 (0.93, 1.07)
P = 0.95
Adjusted 1.00 (0.93, 1.07)
P = 0.99
Gender (female/male) Unadjusted 1.16 (0.75, 1.80)
P = 0.51
Adjusted 1.24 (0.78, 1.96)
P = 0.36
Race (Non-white/White) Unadjusted 1.20 (0.76, 1.87)
P = 0.44
Adjusted 1.13 (0.69, 1.86)
P = 0.62
Ethnicity (Hispanic/Non-Hispanic) Unadjusted 1.39 (0.86, 2.22)
P = 0.18
Adjusted 1.52 (0.86, 2.69)
P = 0.15
EDSS Unadjusted 1.04 (0.86, 1.27)
P = 0.67
Adjusted 1.01 (0.82, 1.23)
P = 0.95
Legend: *: negative binomial regression model, **: linear regression model, †: repea
For negative binomial model, the rate ratio corresponds to a one-unit increase in a
the linear regression model, the estimate is the increase in the log-transformed vol
groups for the other factors. Analyses were adjusted for disease duration and diseaobserved significant associations between race and
log-transformed total T2-LV, as well as race and log-
transformed maximum LV, from unadjusted (pT2-LV =
0.028 and pMax = 0.007) and adjusted analyses (adjusted
pT2-LV = 0.044 and adjusted pMax = 0.011), with higher
measures observed in non-white subjects in both cases.
This association was not found using the log trans-
formed mean T2 lesion size (adjusted p = 0.97). No sig-
nificant differences were observed between white and
non-white subjects in terms of number of T2 lesions
(Table 2) or number of GD + lesions (adjusted p = 0.57).
Ethnicity
There were no statistically significant associations with
any of the T2 lesion measurements and ethnicity. No sig-
nificant associations were observed between Hispanics
and non-Hispanics in relation to number of GD + lesions
(adjusted p = 0.42).
EDSS
There was no significant association between EDSS score
and any of the T2 MRI measures (see Table 2) or number
of GD + lesions (adjusted p = 0.17).
Discussion
Here, we study quantitative lesion characteristics in a mul-




































































ted measures model, EDSS: expanded disability status scale, ^: p-value < 0.05.
ge or EDSS and the difference between the groups for the other factors. For
ume for a one-unit increase in age or EDSS and the difference between the
se modifying therapy duration.
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this cohort and the feasibility of multicenter MRI studies
in this population. Here, we demonstrate that multicenter
quantitative MRI analysis is feasible among U.S. sites in-
cluded in the Pediatric MS Network. We also provide
cross-sectional data on a representative cohort of pediatric
MS patients seen at these sites and associations with
demographic features in this pilot study.
This is one of few studies using volumetric MRI ana-
lysis to assess children with MS, and adds to the limited
knowledge in this patient population. 34% of patients
had at least one gadolinium-enhancing lesion, suggesting
ongoing disease activity in this “real world” cohort of
pediatric MS patients. Our results show a wide range of
both T2 (1–113) and GD + (0–32) lesion numbers in
children with MS in the early phases of disease, demon-
strating considerable heterogeneity amongst subjects.
We also explored potential correlates of this hetero-
geneity with demographic and clinical features. Our ana-
lysis found non-white patients to have a significantly
higher T2–LV and maximum individual T2 lesion size
than white patients. Although our model showed in-
creased T2-LV and maximal T2-LV in non-whites, the
mean T2 lesion size did not differ between whites and
non-whites. This may be explained by the presence of
more large as well as small lesions in the MRIs of non-
whites. Prior results in adults have demonstrated that
African-Americans have a more severe disease than white
patients [15-17]. A small study found that pediatric MS
patients of African-American descent have higher re-
lapse rates than white children [18]. Our results needs
to be replicated, and future studies should account for
referral bias and include specific genetic markers of
familial origin.
Longitudinal studies in adults have associated lesions
larger than 600 mm3 with better recovery, whereas
smaller lesions are associated with increased disability
[19]. Whether this observation in adults applies to le-
sions in patients with pediatric MS warrants additional
investigation in a longitudinal series.
Our results showed a trend towards larger mean T2
lesion size in boys than in girls. However, total T2-LV
and number did not differ according to gender. In previ-
ous studies, pediatric MS patients under the age of
11 years had atypical MRI features with a higher fre-
quency of confluent T2 lesions and fewer well-defined
ovoid lesions than adolescents with MS [20]. We did
not find an association between age and any of the volu-
metric measures studied, although qualitative lesion
measures were not specifically examined.
In our cohort, a higher EDSS score was not signifi-
cantly associated with any of the MRI measures assessed.
This is not surprising given the overall low range of
EDSS scores in our cohort, as well as prior studies inadult MS demonstrating poor correlation of this measure
[21]. Cognitive deficits occur in 30-40% of children with
MS [22,23]. Further studies correlating clinical and cogni-
tive disability with MRI measures are required to provide
insights into the substrate of deficits in pediatric MS.
Limitations of this study include the small number of
subjects and potential referral bias. In addition, the use
of different MRI scanners and slightly different MR
pulse sequence parameters across sites are limitations in
multicenter studies.
Conclusions
This multicenter pilot MRI study has demonstrated as-
sociations of race with lesion measures. As our results
are limited by small numbers and possible referral bias,
this association needs to be validated in larger cohorts
evaluating consecutive children presenting with MS. Add-
itional studies are required to corroborate and further as-
sess the underlying causes of these differences as well as
longitudinal changes in MRI in children and adolescents
with MS including response to specific treatments.
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